2022年欧洲泌尿外科学会指南更新:肾细胞癌辅助免疫检查点抑制剂治疗的应用
基于KEYNOTE-564研究中帕博利珠单抗辅助治疗显著改善高危局限性透明细胞肾细胞癌的无病生存期,欧洲泌尿外科学会肾细胞癌指南专家组2021年给出弱推荐;而阿替利珠单抗、纳武利尤单抗联合伊匹木单抗及围手术期纳武利尤单抗的试验主要无病生存终点均未达到,因异质性不建议做Meta分析。总生存数据尚不成熟,缺乏预测生物标志物,存在不确定性与过度治疗,治疗决策应谨慎并让每位患者参与。
要点
- 帕博利珠单抗仍是目前唯一被推荐用于该辅助治疗场景的免疫检查点抑制剂。
- 阿替利珠单抗、纳武利尤单抗联合伊匹木单抗及围手术期纳武利尤单抗的主要无病生存终点均未达到。
- 因异质性,不建议对这些试验做Meta分析;总生存数据尚不成熟且缺乏预测生物标志物。
核心结论
- 帕博利珠单抗仍是目前唯一被推荐用于高危局限性透明细胞肾细胞癌辅助治疗的免疫检查点抑制剂。
- 总生存数据尚不成熟,缺乏预测结局的生物标志物,存在不确定性且正在发生过度治疗。
- 治疗决策应谨慎并让每位患者参与。
研究设计与样本
- 欧洲泌尿外科学会肾细胞癌指南专家组发布的2022年指南更新,基于KEYNOTE-564等辅助免疫检查点抑制剂试验结果。
- KEYNOTE-564中帕博利珠单抗(PD-1抗体)显著改善高危复发风险的局限性透明细胞肾细胞癌的无病生存期。
- 2021年专家组对高危透明细胞肾细胞癌辅助帕博利珠单抗给出弱推荐,直至最终总生存数据和其他试验结果可用。
- 阿替利珠单抗(PD-L1抑制剂;IMmotion010)、纳武利尤单抗联合伊匹木单抗(CheckMate 914)及围手术期纳武利尤单抗(PROSPER)的主要无病生存终点均未达到。
主要发现
- KEYNOTE-564中辅助帕博利珠单抗显著改善高危局限性透明细胞肾细胞癌的无病生存期。
- IMmotion010中辅助阿替利珠单抗的主要无病生存终点未达到。
- CheckMate 914中辅助纳武利尤单抗联合伊匹木单抗的主要无病生存终点未达到。
- PROSPER中围手术期纳武利尤单抗的主要无病生存终点未达到。
关键数值与推荐
- 2021年欧洲泌尿外科学会肾细胞癌指南专家组对高危透明细胞肾细胞癌辅助帕博利珠单抗给出弱推荐。
- 因异质性,不建议做Meta分析。
- 帕博利珠单抗仍是目前唯一被推荐用于该辅助治疗场景的免疫检查点抑制剂。
临床怎么用
- 治疗决策应谨慎并让每位患者参与。
- 应仔细考虑患者偏好并讨论过度治疗的风险。
- 作者谨慎推荐帕博利珠单抗作为高危肾细胞癌术后辅助治疗。
局限性
- 总生存数据尚不成熟。
- 缺乏预测结局的生物标志物。
- 存在不确定性且正在发生过度治疗。
- 因异质性,不建议做Meta分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In KEYNOTE-564, adjuvant pembrolizumab, a PD-1 antibody, significantly improved disease-free survival (DFS) in localised clear-cell renal cell carcinoma (ccRCC) with a high risk of relapse. In 2021, the European Association of Urology RCC Guidelines Panel issued a weak recommendation for adjuvant pembrolizumab for high-risk ccRCC as defined by the trial until final overall survival data and results from other trials were available. Meanwhile, the primary DFS endpoints were not met for adjuvant atezolizumab (PD-L1 inhibitor; IMmotion010), adjuvant nivolumab plus ipilimumab (CheckMate 914), or perioperative nivolumab (PROSPER). Owing to heterogeneity, a meta-analysis is not recommended. Pembrolizumab remains the only immune checkpoint inhibitor currently recommended in this setting. Overall survival data are immature and biomarkers to predict outcome are lacking. Uncertainty exists and overtreatment is occurring. Treatment decisions should be made with caution and with the involvement of each patient. PATIENT SUMMARY: New results from three trials of immunotherapy after surgery for kidney cancer to reduce the risk of recurrence showed no improvement with these treatments. These results are in contrast to an earlier study that showed that the antibody pembrolizumab did extend the time before kidney cancer recurrence, even though it is not yet clear if overall survival is longer. Thus, we cautiously recommend pembrolizumab as additional treatment in high-risk kidney cancer after surgery, but patient preference should be carefully considered and the risk of overtreatment should be discussed.
引用
- Bedke J, Albiges L, Capitanio U, et al. The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma. Eur Urol. 2022. PMID: 36511268. doi:10.1016/j.eururo.2022.10.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。